撥康視雲治療血管化瞼裂斑創新藥CBT-004在美國完成臨床II期實驗

Cloudbreak Pharma Inc.’s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States Cloudbreak Pharma Inc. has completed the Phase II clinical trial investigating CBT-004 for the treatment of vascularized pinguecula in the United States in April. Preliminary results demonstrated excellent ocular and systemic safety profile. The […]

撥康視雲及參天製藥宣佈就翼狀胬肉創新藥CBT-001簽訂授權協議

Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium   6 August 2024 – Osaka, Japan – Santen Pharmaceutical Co., Ltd. (head office: Osaka, Japan; hereinafter Santen), a specialist in ophthalmology, and Cloudbreak Pharma Inc. (head office: California, US; hereinafter Cloudbreak), a clinical stage ophthalmic drug company, announce the […]